期刊
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 10, 期 1, 页码 1-12出版社
SHENYANG PHARMACEUTICAL UNIV
DOI: 10.1016/j.ajps.2014.08.011
关键词
RNA interference; Cancer therapy; Delivery systems; siRNA
Since the discovery of the Nobel prize-winning mechanism of RNA interference (RNAi) ten years ago, it has become a promising drug target for the treatment of multiple diseases, including cancer. There have already been some successful applications of siRNA drugs in the treatment of age-related macular degeneration and respiratory syncytial virus infection. However, significant barriers still exist on the road to clinical applications of siRNA drugs, including poor cellular uptake, instability under physiological conditions, off-target effects and possible immunogenicity. The successful application of siRNA for cancer therapy requires the development of clinically suitable, safe and effective drug delivery systems. Herein, we review the design criteria for siRNA delivery systems and potential siRNA drug delivery systems for cancer therapy, including chemical modifications, lipid-based nanovectors, polymer-mediated delivery systems, conjugate delivery systems, and others. (C) 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据